Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Search Results to Walter M. Stadler

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Stadler, Walter M.

Item TypeName
Concept Niacinamide
Academic Article Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
Academic Article Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Academic Article Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
Academic Article Sorafenib in advanced clear-cell renal-cell carcinoma.
Academic Article Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Academic Article Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Academic Article Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Academic Article New therapeutic options for renal cell carcinoma.
Academic Article Sorafenib.
Academic Article Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
Academic Article Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Academic Article Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
Academic Article Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
Academic Article Resampling phase III data to assess phase II trial designs and endpoints.
Academic Article Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Academic Article Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
Academic Article Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis.
Academic Article Estimation of renal cell carcinoma treatment effects from disease progression modeling.
Academic Article Maturing of renal cancer therapeutics.
Academic Article Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Search Criteria
  • Niacinamide